US PATENT GRANTED TO ARDANA FOR TEVERELIX LA

Edinburgh, UK, 31 August 2006;  Ardana plc (LSE: ARA), the pharmaceutical company focused on improving human reproductive health, today announces that it has been granted a US patent, number 7,098,305, covering the long acting formulation of its GnRH antagonist, Teverelix (Teverelix LA).

The patent is subject to a US patent term adjustment (i.e. extension), which means that it is not due to expire in the US until April 2023.

This patent forms part of Ardana’s growing intellectual property portfolio around its research and development activities.

Teverelix is Ardana’s lead development compound and is in Phase II clinical trials in two indications; prostate cancer and benign prostatic hyperplasia, with Phase I studies ongoing in endometriosis. 

-- ENDS --

back to top